Coloplast Agrees to Buy Biotechnology Firm Kerecis for Up to $1.3 Billion
By Dominic Chopping
Danish medical device manufacturer Coloplast said Friday it has agreed to buy wound-care provider Kerecis for up to $1.3 billion.
Kerecis is a biotechnology company that has developed a technology using fish skin to treat wounds, burns and other complex wounds relating to diabetes, veins, trauma, and surgery.
Based in Iceland, it uses skin from fish caught in its local waters and has around 500 employees globally, of which more than two-thirds are in the U.S.
The company will pay $1.2 billion upfront in cash with an earnout potential of up to $100 million and is expected to be financed through an equity capital raise of around 9 billion Danish kroner ($1.32 billion).
The Danish company said the acquisition is expected to accelerate its group organic growth by around one percentage point as of full-year 2024/25 but will be margin dilutive in the short-term.
As a result of the acquisition, Coloplast said it has raised its long-term organic growth guidance to 8%-10%, from 7%-9%, and maintained its long-term earnings before interest and tax margin guidance at more than 30%. However, the EBIT margin in its 2025 strategy is now expected to remain below 30%, having targeted a margin of over 30%.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
July 07, 2023 03:46 ET (07:46 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations